type 2 diabetes
Endocrinology · 2005–2026
108decisions
42medicines
21carried consumer input
255individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tirzepatide Treatment of adults with type 2 diabetes mellitus inadequately controlled with metformin, sulfonylurea, and/or insulin, who have failed or are… | Mar 2026 | Recommended with restriction | 115 individuals |
| tirzepatide Treatment of adults with type 2 diabetes mellitus that is inadequately controlled despite use of metformin, sulfonylurea, and/or insulin, or in patients with… | Jul 2025 | Deferred | 115 individuals |
| pioglitazone Treatment of type 2 diabetes mellitus (T2DM). The submission requested listing of new 30-pack sizes of pioglitazone tablets (15 mg, 30 mg, and 45 mg strengths)… | May 2025 | Recommended | none received |
| dapagliflozin with sitagliptin Treatment of patients with Type 2 diabetes mellitus with inadequate response to dual therapy with metformin and either a SGLT2 inhibitor or a DPP4 inhibitor,… | Mar 2024 | Recommended with restriction | input received |
| semaglutide Type 2 diabetes mellitus (T2DM). New strength (2 mg in 3 mL pre-filled pen) for initial treatment and continuing treatment, as a substitute formulation for the… | Nov 2024 | Recommended with restriction | 5 individuals |
| tirzepatide Treatment of adults with inadequately controlled type 2 diabetes mellitus who have comorbid severe obesity or identify as Aboriginal and Torres Strait… | Nov 2024 | Not recommended | 14 individuals |
| tirzepatide Treatment of adult patients with inadequately controlled type 2 diabetes as dual therapy in combination with metformin. | Jul 2023 | Not recommended | 2 individuals |
| semaglutide Type 2 diabetes, available on the PBS for use in combination with metformin and/or sulfonylurea or with insulin. This submission relates to temporary supply of… | Aug 2022 | Recommended with restriction | no section in document |
| dulaglutide Type 2 diabetes mellitus in patients who require treatment intensification to achieve glycaemic targets as dual therapy with metformin, specifically in those… | May 2022 | Recommended | 1 individuals Diabetes Australia |
| dulaglutide Treatment of type 2 diabetes. The submission concerns temporary supply of an overseas-sourced version to address shortage caused by increased demand due to… | Oct 2022 | Recommended with restriction | no section in document |
| semaglutide Treatment of Type 2 Diabetes Mellitus in combination with insulin and metformin (unless contraindicated or not tolerated) in patients with inadequate glycaemic… | Mar 2021 | Recommended with restriction | input received |
| dulaglutide Type 2 diabetes mellitus in combination with insulin and metformin (unless contraindicated or not tolerated). | Jul 2020 | Recommended | none received |
| semaglutide Treatment of adults with Type 2 Diabetes Mellitus with inadequate glycaemic control as dual therapy in combination with metformin or a sulfonylurea where… | Mar 2020 | Recommended | none received |
| exenatide Type 2 diabetes mellitus in patients with inadequate glycaemic control on metformin and/or a sulfonylurea, for use as second- or third-line therapy. | Mar 2019 | Not recommended | none received |
| insulin glargine with lixisenatide Treatment of adults with Type 2 diabetes mellitus who have inadequate glycaemic control with basal insulin, in combination with metformin or where metformin is… | Mar 2019 | Not recommended | 1 individuals |
| dulaglutide Type 2 diabetes mellitus in patients with inadequate glycaemic control despite treatment with insulin (and metformin, if not contraindicated or not tolerated),… | Nov 2019 | Deferred | input received |
| semaglutide Treatment of patients with type 2 diabetes who have inadequate glycaemic control, as dual therapy in combination with metformin or a sulfonylurea where either… | Nov 2019 | Recommended | input received |
| ertugliflozin Type 2 diabetes mellitus in patients inadequately controlled with metformin or a sulfonylurea, for dual oral therapy with metformin or a sulfonylurea (15 mg… | Jul 2018 | Recommended with restriction | none received |
| ertugliflozin with sitagliptin Type 2 diabetes mellitus in patients inadequately controlled on dual oral therapy with metformin and a dipeptidyl peptidase 4 inhibitor or sodium-glucose… | Jul 2018 | Recommended with restriction | none received |
| ertugliflozin Type 2 diabetes mellitus in patients inadequately controlled with metformin or a sulfonylurea, for use in dual oral therapy with metformin or a sulfonylurea. | Mar 2018 | Recommended with restriction | none received |
| insulin degludec with insulin aspart Treatment of adult patients with diabetes mellitus where insulin treatment is necessary. IDegAsp is indicated for improvement of glycaemic control in adult… | Mar 2018 | Recommended | none received |
| insulin glargine with lixisenatide Type 2 diabetes mellitus in adults with inadequate glycaemic control with basal insulin, to be used in combination with metformin. | Mar 2018 | Not recommended | input received Diabetes Australia |
| insulin glargine with lixisenatide Type 2 diabetes mellitus in patients with inadequate glycaemic control on basal insulin, in combination with metformin. | Mar 2018 | Not recommended | input received Diabetes Australia |
| liraglutide Type 2 diabetes mellitus, specifically for dual combination therapy with metformin or a sulfonylurea, and triple combination therapy with metformin and a… | Mar 2018 | Not recommended | none received |
| dapagliflozin with metformin Type 2 diabetes mellitus as triple oral therapy in combination with a dipeptidyl peptidase 4 (DPP4) inhibitor in patients uncontrolled on dual oral therapy. | Jul 2017 | Deferred | none received |
| dapagliflozin Type 2 diabetes in adults with inadequate glycaemic control on dual therapy with metformin and a DPP4 inhibitor, as add-on triple oral therapy. | Jul 2017 | Deferred | none received |
| dapagliflozin/saxagliptin Type 2 diabetes in adults with inadequate glycaemic control on dual therapy of metformin and a dipeptidyl peptidase 4 (DPP4) inhibitor. | Jul 2017 | Deferred | none received |
| liraglutide Treatment of patients with Type 2 diabetes mellitus and high cardiovascular risk as dual therapy with metformin or a sulfonylurea, triple therapy with… | Jul 2017 | Not recommended | input received |
| empagliflozin with linagliptin Type 2 diabetes mellitus as triple oral therapy in combination with metformin in patients intolerant or contraindicated to a combination of metformin and a… | Mar 2017 | Not recommended | none received |
| dapagliflozin Type 2 Diabetes Mellitus in triple oral therapy with a dipeptidyl peptidase 4 inhibitor (DPP4 inhibitor/gliptin) and metformin in patients who have previously… | Nov 2017 | Recommended with restriction | none received |
| dulaglutide Type 2 diabetes mellitus as dual therapy in combination with metformin and triple therapy in combination with metformin and sulfonylurea in patients not… | Nov 2017 | Recommended | input received |
| empagliflozin, empagliflozin with metformin, linagliptin, linagliptin with metformin Type 2 Diabetes Mellitus in patients uncontrolled on dual oral therapy, for use in triple oral therapy (DPP4 inhibitor + SGLT2 inhibitor + metformin). | Nov 2017 | Recommended with restriction | none received |
| empagliflozin with linagliptin Type 2 diabetes mellitus in patients uncontrolled on dual oral therapy with either a DPP4 inhibitor or SGLT2 inhibitor in combination with metformin; also for… | Nov 2017 | Recommended with restriction | none received |
| vildagliptin Treatment of type 2 diabetes mellitus in patients not adequately controlled on insulin therapy with or without metformin, for use in combination with insulin. | Nov 2017 | Recommended with restriction | none received |
| exenatide Type 2 diabetes mellitus in combination with metformin and/or a sulfonylurea in patients who have not achieved adequate glycaemic control. | Mar 2016 | Recommended with restriction | no section in document |
| linagliptin Type 2 diabetes mellitus as triple oral therapy in combination with metformin and a sulfonylurea when dual therapy does not provide adequate glycaemic control. | Mar 2016 | Recommended with restriction | none received |
| linagliptin Type 2 diabetes in combination with insulin, with or without metformin, when therapy with insulin (± metformin) does not provide adequate glycaemic control. | Mar 2016 | Recommended with restriction | none received |
| vildagliptin Type 2 diabetes as triple oral combination therapy with metformin and a sulfonylurea when combination therapy with both agents does not provide adequate… | Mar 2016 | Recommended with restriction | none received |
| dapagliflozin and metformin extended release Treatment of type 2 diabetes mellitus in adults as add-on to insulin therapy or as triple oral therapy in combination with a sulfonylurea. | Jul 2015 | Recommended | no section in document |
| exenatide Type 2 diabetes mellitus as dual therapy (with metformin or a sulfonylurea) or triple therapy (with metformin and a sulfonylurea) in patients with HbA1c… | Jul 2015 | Recommended with restriction | 1 individuals |
| saxagliptin and metformin extended release Extension of PBS indication for saxagliptin+metformin XR to include use in combination with a sulfonylurea (triple oral therapy) for the treatment of type 2… | Jul 2015 | Recommended | none received |
| saxagliptin Treatment of patients with type 2 diabetes mellitus in combination with metformin and a sulfonylurea (triple oral therapy). | Jul 2015 | Recommended | input received |
| sitagliptin Type 2 diabetes mellitus as part of triple oral therapy with metformin and a sulfonylurea when therapy with both agents does not provide adequate glycaemic… | Jul 2015 | Recommended | none received |
| sitagliptin Treatment of type 2 diabetes mellitus in combination with insulin, with or without metformin. | Jul 2015 | Not recommended | none received |
| dapagliflozin Type 2 diabetes mellitus in combination with metformin and a sulfonylurea (triple oral therapy). | Mar 2015 | Recommended | input received |
| exenatide Type 2 diabetes mellitus in combination with insulin (basal insulin with or without metformin). Proposed as an alternative to insulin intensification with… | Mar 2015 | Recommended with restriction | 1 individuals |
| empagliflozin Type 2 diabetes in combination with insulin, with or without metformin, when therapy with insulin (± metformin) does not provide adequate glycaemic control. | Nov 2015 | Recommended | none received |
| empagliflozin/metformin Type 2 diabetes mellitus where metformin alone does not provide adequate glycaemic control. Empagliflozin/metformin fixed dose combination provides a treatment… | Nov 2015 | Recommended | none received |
| sitagliptin Type 2 diabetes mellitus in combination with insulin, with or without metformin, in patients with inadequate glycaemic control despite insulin treatment with… | Nov 2015 | Not recommended | none received |
| empagliflozin Type 2 diabetes mellitus as triple therapy in combination with metformin and a sulfonylurea when treatment with both agents does not provide adequate glycaemic… | Nov 2015 | Recommended | none received |
| dapagliflozin and metformin extended release Treatment of type 2 diabetes in patients whose condition cannot be adequately controlled by metformin and a sulfonylurea, as a third-line therapy. | Jul 2014 | Recommended with restriction | none received |
| dapagliflozin Diabetes mellitus type 2 (T2DM) in combination with metformin or a sulfonylurea when the condition cannot be adequately controlled by treatment with metformin… | Jul 2014 | Not recommended | no section in document |
| empagliflozin Treatment of type 2 diabetes in combination with metformin or a sulfonylurea in patients unable to be adequately controlled by treatment with metformin and a… | Jul 2014 | Recommended with restriction | none received |
| glucose indicator blood strip Blood glucose monitoring in patients receiving treatment under a GP Management Plan or Team Care Arrangements. | Jul 2014 | Recommended | no section in document |
| lixisenatide Treatment of type 2 diabetes mellitus in combination with metformin (dual therapy) or in combination with metformin and a sulphonylurea (triple therapy). | Jul 2014 | Not recommended | input received |
| lixisenatide Treatment of type 2 diabetes in combination with insulin, in patients with inadequate glycaemic control despite treatment with insulin and oral antidiabetic… | Jul 2014 | Not recommended | none received |
| thiazolidinediones, glucagon-like peptide-1 receptor agonists, sodium-glucose co-transporter 2 inhibitors Third-line treatment of type 2 diabetes mellitus after failure of first and second-line treatment options. | Jul 2014 | Deferred | no section in document |
| dapagliflozin Type 2 diabetes in combination with insulin in patients with inadequate glycaemic control despite treatment with insulin and oral antidiabetic agents, or… | Nov 2014 | Recommended | input received |
| glucose indicator blood strip Blood glucose monitoring in patients receiving treatment under a GP Management Plan or Team Care Arrangements. | Nov 2014 | Recommended with restriction | no section in document |
| alogliptin Type 2 diabetes mellitus in combination with metformin or a sulfonylurea in patients whose HbA1c is greater than 7% despite treatment with either metformin or… | Jul 2013 | Recommended with restriction | no section in document |
| canagliflozin Type 2 diabetes mellitus as dual oral combination therapy with metformin or a sulfonylurea in patients whose HbA1c is greater than 7% despite treatment with… | Jul 2013 | Recommended with restriction | no section in document |
| vildagliptin/metformin Type 2 diabetes mellitus as triple oral combination therapy (vildagliptin/metformin fixed-dose combination with a sulfonylurea) in patients with HbA1c greater… | Jul 2013 | Recommended | no section in document |
| vildagliptin Type 2 diabetes mellitus as triple oral combination therapy with metformin and a sulfonylurea in patients whose HbA1c is greater than 7% despite maximally… | Jul 2013 | Not recommended | no section in document |
| dapagliflozin Type 2 diabetes mellitus as dual oral combination therapy with metformin or a sulfonylurea in patients whose HbA1c is greater than 7% prior to initiation and… | Jul 2013 | Recommended with restriction | no section in document |
| saxagliptin with metformin Type 2 diabetes mellitus in patients whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor, thiazolidinedione or… | Apr 2013 | Recommended | no section in document |
| linagliptin with metformin hydrochloride Type 2 diabetes mellitus in patients with HbA1c >7% despite metformin monotherapy, where metformin-sulfonylurea combination is contraindicated or not… | Mar 2013 | Deferred | no section in document |
| linagliptin with metformin hydrochloride Type 2 diabetes mellitus in patients with HbA1c greater than 7% despite treatment with metformin, where a combination of metformin and a sulfonylurea is… | Mar 2013 | Recommended | no section in document |
| liraglutide Treatment of type 2 diabetes as dual combination therapy with metformin or a sulfonylurea in patients for whom a combination of metformin and a sulfonylurea is… | Mar 2013 | Recommended with restriction | unclear |
| saxagliptin with metformin Type 2 diabetes mellitus in patients with HbA1c greater than 7% despite treatment with metformin, where a combination of metformin and a sulfonylurea is… | Mar 2013 | Deferred | no section in document |
| alogliptin with metformin Type 2 diabetes mellitus in patients whose HbA1c is greater than 7% despite treatment with metformin, without requiring prior intolerance or contraindication… | Nov 2013 | Recommended with restriction | no section in document |
| metformin and saxagliptin Treatment of type 2 diabetes mellitus in patients with HbA1c greater than 7% despite treatment with metformin, where a combination of metformin and a… | Nov 2013 | Recommended with restriction | no section in document |
| metformin and sitagliptin Type 2 diabetes mellitus in patients whose HbA1c is greater than 7% despite treatment with metformin, for initiation of a dipeptidyl peptidase 4 inhibitor,… | Nov 2013 | Recommended | no section in document |
| exenatide Type 2 diabetes mellitus in dual combination therapy with metformin or a sulfonylurea, or in triple combination therapy with metformin and a sulfonylurea, in… | Nov 2013 | Recommended with restriction | no section in document |
| linagliptin Treatment of patients with type 2 diabetes in combination with metformin and a sulfonylurea (triple therapy) | Jul 2012 | Not recommended | no section in document |
| saxagliptin Type 2 diabetes, in combination with insulin, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin),… | Jul 2012 | Not recommended | no section in document |
| linagliptin Treatment of patients with type 2 diabetes in combination with metformin and a sulfonylurea (triple therapy) when HbA1c is greater than 7% despite maximally… | Jul 2012 | Not recommended | no section in document |
| saxagliptin Treatment of type 2 diabetes in combination with insulin in patients whose HbA1c is greater than 7% despite treatment with insulin and oral anti-diabetic… | Jul 2012 | Not recommended | no section in document |
| Dapagliflozin Type 2 diabetes in combination with metformin or a sulfonylurea. | Mar 2012 | Not recommended | no section in document |
| dapagliflozin Type 2 diabetes, in combination with insulin, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin),… | Mar 2012 | Not recommended | no section in document |
| dapagliflozin Type 2 diabetes mellitus in combination with metformin or a sulfonylurea, in patients whose HbA1c is greater than 7% despite treatment with either agent and… | Mar 2012 | Not recommended | no section in document |
| dapagliflozin Type 2 diabetes, in combination with insulin, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin),… | Mar 2012 | Rejected | no section in document |
| sitagliptin with simvastatin For use in patients with type 2 diabetes who are currently receiving treatment with simvastatin and who satisfy the criteria for prescribing DPP-4 inhibitors. | Nov 2012 | Recommended with restriction | no section in document |
| sitagliptin with simvastatin Type 2 diabetes mellitus and hypercholesterolaemia in patients currently receiving treatment with simvastatin and who satisfy the criteria for prescribing… | Nov 2012 | Recommended with restriction | no section in document |
| exenatide Type 2 diabetes mellitus in combination with metformin or a sulfonylurea, and in triple combination therapy with metformin and a sulfonylurea, in patients who… | Jul 2011 | Not recommended | no section in document |
| linagliptin Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl… | Jul 2011 | Recommended | no section in document |
| linagliptin Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl… | Jul 2011 | Recommended | no section in document |
| liraglutide Dual combination therapy with metformin or a sulphonylurea in patients for whom a combination of metformin and a sulphonylurea is contraindicated or not… | Nov 2011 | Not recommended | unclear |
| linagliptin Type 2 diabetes mellitus in combination with metformin or a sulfonylurea, in patients with HbA1c >7% despite treatment with either metformin or a sulfonylurea… | Nov 2011 | Recommended with restriction | no section in document |
| saxagliptin Type 2 diabetes mellitus, in combination with metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7 % despite treatment with either metformin… | Mar 2010 | Recommended with restriction | no section in document |
| vildagliptin Type 2 diabetes mellitus in combination with metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a DPP-4 inhibitor… | Mar 2010 | Recommended with restriction | no section in document |
| vildagliptin Type 2 diabetes mellitus in combination with metformin or a sulfonylurea in patients whose HbA1c is greater than 7% despite treatment with either agent alone,… | Mar 2010 | Recommended with restriction | no section in document |
| liraglutide Type 2 diabetes mellitus patients as combination therapy with metformin and a sulfonylurea (triple therapy) or combination therapy with metformin or a… | Nov 2010 | Not recommended | no section in document |
| exenatide Adjunctive therapy in patients with type 2 diabetes mellitus not achieving adequate glycaemic control despite optimal therapy with metformin and/or a… | Mar 2008 | Recommended | no section in document |
| sitagliptin phosphate Type 2 diabetes mellitus in combination with metformin or a sulfonylurea, where HbA1c remains greater than 7% despite monotherapy and where combination with… | Mar 2008 | Recommended with restriction | no section in document |
| exenatide Adjunctive therapy to improve glycaemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea or a combination of… | Nov 2008 | Recommended with restriction | no section in document |
| exenatide Adjunctive therapy for adults with type 2 diabetes who are taking metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea but are not… | Jul 2007 | Not recommended | no section in document |
| exenatide Adjunctive therapy in patients with type 2 diabetes who are no longer achieving glycaemic control despite optimal therapy with metformin and/or a sulfonylurea. | Jul 2007 | Not recommended | no section in document |
| Insulin detemir people with type 2 diabetes who are not responsive to oral hypoglycaemic drugs | Nov 2007 | Recommended with restriction | no section in document |
| pioglitazone hydrochloride Triple oral combination therapy with metformin and a sulfonylurea for the treatment of type 2 diabetes mellitus in patients who have an HbA1c greater than 7%… | Nov 2007 | Recommended with restriction | no section in document |
| Rosiglitazone maleate Type 2 diabetes, alone or in combination with other diabetes therapies, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione… | Nov 2007 | Not recommended | no section in document |
| insulin detemir Extension of listing to include people with type 2 diabetes who are not responsive to oral hypoglycaemic drugs. Previously listed for type 1 diabetes. | Nov 2007 | Recommended with restriction | no section in document |
| pioglitazone hydrochloride Type 2 diabetes mellitus in combination with metformin and a sulfonylurea in patients with HbA1c greater than 7% despite maximally tolerated doses of metformin… | Nov 2007 | Recommended with restriction | no section in document |
| rosiglitazone maleate Type 2 diabetes mellitus, alone or in combination with other diabetes therapies, in patients whose HbA1c is greater than 7% prior to initiation of a… | Nov 2007 | Not recommended | no section in document |
| rosiglitazone maleate with metformin hydrochloride type 2 diabetes mellitus, for use in combination therapy or as part of triple therapy when used in combination with a sulfonylurea, and for initiation of… | Jul 2006 | Recommended with restriction | no section in document |
| rosiglitazone maleate with metformin hydrochloride Type 2 diabetes mellitus in patients with inadequate glycaemic control on metformin alone or in combination with a sulfonylurea, for dual therapy or triple… | Jul 2006 | Recommended with restriction | no section in document |
| insulin detemir Treatment of Type 1 or Type 2 diabetes patients requiring intensive insulin therapy with 3 or more injections of insulin per day, and Type 1 patients with a… | Mar 2006 | Recommended with restriction | no section in document |
| insulin glargine For the treatment of Type 1 diabetes; For the treatment of Type 2 diabetes when used in combination with three or more prandial doses of insulin per day; For… | Mar 2006 | Recommended | no section in document |
| insulin detemir Treatment of diabetes mellitus where used as basal insulin in combination with meal-related short- or rapid-acting insulin. | Jul 2005 | Recommended | no section in document |
Who spoke
Diabetes Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 21 of 59 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.